Vol 16, No 3 (2022)
Review paper
Published online: 2022-07-04

open access

Page views 3901
Article views/downloads 464
Get Citation

Connect on Social Media

Connect on Social Media

Ten reasons to consider cannabinoids in everyday clinical practice

Agata Lewandowska1, Michał Graczyk2
Palliat Med Pract 2022;16(3):167-182.

Abstract

Medical cannabis is attracting more and more interest among both patients and healthcare professionals.
Despite the long history of using this plant for medicinal purposes, the current approach to medicine,
which is primarily based on facts, forces us to take a scientific approach in the selection of products
and substances from the cannabinoid group. More and more scientific and clinical studies are providing
evidence of their effectiveness. Clinical trials with small groups of patients as well as case reports show
the benefits of medical cannabis, while larger trials often do not confirm clear improvement compared
to other available treatments. Both physicians and their patients need to know in which indications
clinical benefits are possible and whether the proposed therapy is safe. Only after analysing the patient’s
history, interviewing and examining, in a highly individualized and detailed manner (including relative
and absolute contraindications) can cannabinoid therapy be considered. They are more often used as an
addition to basic and standard therapy, which can improve its effectiveness. Less frequently we choose
cannabinoids as drugs of the first choice used in monotherapy. The article aims to present 10 reasons
why cannabinoids are worth considering for use in everyday clinical practice and to prepare practitioners
to answer the questions most asked by patients.

Article available in PDF format

View PDF Download PDF file

References

  1. Schrot RJ, Hubbard JR. Cannabinoids: Medical implications. Ann Med. 2016; 48(3): 128–141.
  2. Groce E. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Journal of Medical Regulation. 2018; 104(4): 32–32.
  3. Badowski ME. A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics. Cancer Chemother Pharmacol. 2017; 80(3): 441–449.
  4. Busse JW, Vankrunkelsven P, Zeng L, et al. Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline. BMJ. 2021; 374: n2040.
  5. Ziemianski D, Capler R, Tekanoff R, et al. Cannabis in medicine: a national educational needs assessment among Canadian physicians. BMC Med Educ. 2015; 15(1): 52.
  6. McLennan A, Kerba M, Subnis U, et al. Health care provider preferences for, and barriers to, cannabis use in cancer care. Curr Oncol. 2020; 27(2): e199–e205.
  7. Graczyk M, Lewandowska AA, Dzierżanowski T. The Therapeutic Potential of Cannabis in Counteracting Oxidative Stress and Inflammation. Molecules. 2021; 26(15).
  8. Gallego-Landin I, García-Baos A, Castro-Zavala A, et al. Reviewing the Role of the Endocannabinoid System in the Pathophysiology of Depression. Front Pharmacol. 2021; 12: 762738.
  9. Lucas Luz W, Santos-Silva M, Cardoso PB, et al. Putative Activation of the CB1 Cannabinoid Receptors Prevents Anxiety-Like Behavior, Oxidative Stress, and GABA Decrease in the Brain of Zebrafish Submitted to Acute Restraint Stress. Front Behav Neurosci. 2020; 14: 598812.
  10. Cheung KA, Peiris H, Wallace G, et al. The Interplay between the Endocannabinoid System, Epilepsy and Cannabinoids. Int J Mol Sci. 2019; 20(23).
  11. Lafaye G, Karila L, Blecha L, et al. Cannabis, cannabinoids, and health. Dialogues Clin Neurosci. 2017; 19(3): 309–316.
  12. Espinosa-Jovel C. Cannabinoids in epilepsy: Clinical efficacy and pharmacological considerations. Neurologia (Engl Ed). 2020 [Epub ahead of print].
  13. Woroń J, Przeklasa-Muszyńska A, Dobrogowski J. Cannabinoids in pain treatment in 2019: What we know and what more we should learn. Med Bólu Terapia. 2019; 7(378): 41–46.
  14. Lucas P. Cannabis as an adjunct to or substitute for opiates in the treatment of chronic pain. J Psychoactive Drugs. 2012; 44(2): 125–133.
  15. Iyer V, Slivicki RA, Thomaz AC, et al. Positive Allosteric Modulation of CB Cannabinoid Receptor Signaling Enhances Morphine Antinociception and Attenuates Morphine Tolerance Without Enhancing Morphine- Induced Dependence or Reward. Front Mol Neurosci. 2020; 13: 54.
  16. Yuill MB, Hale DE, Guindon J, et al. Anti-nociceptive interactions between opioids and a cannabinoid receptor 2 agonist in inflammatory pain. Mol Pain. 2017; 13: 1744806917728227.
  17. Johnson SP, Chung KC, Zhong L, et al. Risk of Prolonged Opioid Use Among Opioid-Naïve Patients Following Common Hand Surgery Procedures. J Hand Surg Am. 2016; 41(10): 947–957.e3.
  18. Zhou J, Ma R, Jin Y, et al. Molecular mechanisms of opioid tolerance: From opioid receptors to inflammatory mediators (Review). Exp Ther Med. 2021; 22(3): 1004.
  19. Wiese B, Wilson-Poe AR. Emerging Evidence for Cannabis' Role in Opioid Use Disorder. Cannabis Cannabinoid Res. 2018; 3(1): 179–189.
  20. Toor T, Murphy E, Simmons AN, et al. Craving of prescription opioids among veterans with chronic pain. Pain. 2022 [Epub ahead of print].
  21. Bulls HW, Chu E, Goodin BR, et al. Framework for opioid stigma in cancer pain. Pain. 2022; 163(2): e182–e189.
  22. Graczyk M, Borkowska A, Krajnik M. Why patients are afraid of opioid analgesics: a study on opioid perception in patients with chronic pain. Pol Arch Intern Med. 2018; 128(2): 89–97.
  23. Liang YC, Huang CC, Hsu KS. Therapeutic potential of cannabinoids in trigeminal neuralgia. Curr Drug Targets CNS Neurol Disord. 2004; 3(6): 507–514.
  24. Grant I. Medicinal cannabis and painful sensory neuropathy. Virtual Mentor. 2013; 15(5): 466–469.
  25. Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007; 68(7): 515–521.
  26. Moulin D, Boulanger A, Clark AJ, et al. Canadian Pain Society. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014; 19(6): 328–335.
  27. Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ. 2010; 182(14): E694–E701.
  28. Parolaro D, Rubino T, Viganò D, et al. Cellular mechanisms underlying the interaction between cannabinoid and opioid system. Curr Drug Targets. 2010; 11(4): 393–405.
  29. Capano A, Weaver R, Burkman E. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. Postgrad Med. 2020; 132(1): 56–61.
  30. Henderson LA, Kotsirilos V, Cairns EA, et al. Medicinal cannabis in the treatment of chronic pain. Aust J Gen Pract. 2021; 50(10): 724–732.
  31. Takakuwa KM, Hergenrather JY, Shofer FS, et al. The Impact of Medical Cannabis on Intermittent and Chronic Opioid Users with Back Pain: How Cannabis Diminished Prescription Opioid Usage. Cannabis Cannabinoid Res. 2020; 5(3): 263–270.
  32. Pritchard ER, Dayer L, Belz J, et al. Effect of cannabis on opioid use in patients with cancer receiving palliative care. J Am Pharm Assoc (2003). 2020; 60(1): 244–247.
  33. Cooke AC, Knight KR, Miaskowski C. Patients' and clinicians' perspectives of co-use of cannabis and opioids for chronic non-cancer pain management in primary care. Int J Drug Policy. 2019; 63: 23–28.
  34. Abrams DI, Couey P, Shade SB, et al. Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther. 2011; 90(6): 844–851.
  35. MacCallum CA, Eadie L, Barr AM, et al. Practical Strategies Using Medical Cannabis to Reduce Harms Associated With Long Term Opioid Use in Chronic Pain. Front Pharmacol. 2021; 12: 633168.
  36. Desroches J, Beaulieu P. Opioids and cannabinoids interactions: involvement in pain management. Curr Drug Targets. 2010; 11(4): 462–473.
  37. Almog S, Aharon-Peretz J, Vulfsons S, et al. The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial. Eur J Pain. 2020; 24(8): 1505–1516.
  38. Longo R, Oudshoorn A, Befus D. Cannabis for Chronic Pain: A Rapid Systematic Review of Randomized Control Trials. Pain Manag Nurs. 2021; 22(2): 141–149.
  39. Haroutiunian S, Rosen G, Shouval R, et al. Open-label, add-on study of tetrahydrocannabinol for chronic nonmalignant pain. J Pain Palliat Care Pharmacother. 2008; 22(3): 213–217.
  40. Narang S, Gibson D, Wasan AD, et al. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain. 2008; 9(3): 254–264.
  41. Blake A, Wan BoA, Malek L, et al. A selective review of medical cannabis in cancer pain management. Ann Palliat Med. 2017; 6(Suppl 2): S215–S222.
  42. The National Academies of Science Engineering. The health effects of Cannabis and Cannabinoids. Committee’s conclusions. The National Academies of Science Engineering and Medicine. Natl Acad Press. Published online 2018.
  43. Serafimovska T, Darkovska-Serafimovska M, Stefkov G, et al. Pharmacotherapeutic Considerations for Use of Cannabinoids to Relieve Symptoms of Nausea and Vomiting Induced by Chemotherapy. Folia Med (Plovdiv). 2020; 62(4): 668–678.
  44. Parker LA, Rock EM, Limebeer CL. Regulation of nausea and vomiting by cannabinoids. Br J Pharmacol. 2011; 163(7): 1411–1422.
  45. Meiri E, Jhangiani H, Vredenburgh JJ, et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin. 2007; 23(3): 533–543.
  46. Smith LA, Azariah F, Lavender VTC, et al. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev. 2015(11): CD009464.
  47. Tramèr MR, Carroll D, Campbell FA, et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ. 2001; 323(7303): 16–21.
  48. Rock EM, Parker LA. Cannabinoids As Potential Treatment for Chemotherapy-Induced Nausea and Vomiting. Front Pharmacol. 2016; 7: 221.
  49. Radbruch L, Nauck F. Review of cannabinoids in the treatment of nausea and vomiting. Schmerz. 2004; 18(4): 306–310.
  50. Morales M, Corsi O, Peña J. Are cannabinoids effective for the management of chemotherapy induced nausea and vomiting? Medwave. 2017; 17(9): e7119.
  51. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015; 313(24): 2456–2473.
  52. Todaro B. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting. J Natl Compr Canc Netw. 2012; 10(4): 487–492.
  53. Jones É, Vlachou S. A Critical Review of the Role of the Cannabinoid Compounds Δ-Tetrahydrocannabinol (Δ-THC) and Cannabidiol (CBD) and their Combination in Multiple Sclerosis Treatment. Molecules. 2020; 25(21).
  54. Notcutt WG. Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis. Neurotherapeutics. 2015; 12(4): 769–777.
  55. Nielsen S, Murnion B, Campbell G, et al. Cannabinoids for the treatment of spasticity. Dev Med Child Neurol. 2019; 61(6): 631–638.
  56. Braley TJ, Whibley D, Alschuler KN, et al. Cannabinoid use among Americans with MS: Current trends and gaps in knowledge. Mult Scler J Exp Transl Clin. 2020; 6(3): 2055217320959816.
  57. Rice J, Hugos C, Hildebrand A, et al. Cannabis use in people with multiple sclerosis and spasticity: A cross-sectional analysis. Mult Scler Relat Disord. 2020; 41: 102009.
  58. Zajicek JP, Hobart JC, Slade A, et al. MUSEC Research Group. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry. 2012; 83(11): 1125–1132.
  59. Zajicek J, Fox P, Sanders H, et al. UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003; 362(9395): 1517–1526.
  60. Notcutt W, Langford R, Davies P, et al. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols). Mult Scler. 2012; 18(2): 219–228.
  61. Sagredo O, Pazos MR, Valdeolivas S, et al. Cannabinoids: novel medicines for the treatment of Huntington's disease. Recent Pat CNS Drug Discov. 2012; 7(1): 41–48.
  62. Leussink VI, Husseini L, Warnke C, et al. Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity. Ther Adv Neurol Disord. 2012; 5(5): 255–266.
  63. Torres-Moreno MC, Papaseit E, Torrens M, et al. Assessment of Efficacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple Sclerosis: A Systematic Review and Meta-analysis. JAMA Netw Open. 2018; 1(6): e183485.
  64. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry. 2005; 76(12): 1664–1669.
  65. Notcutt WG. A questionnaire survey of patients and carers of patients prescribed Sativex as an unlicensed medicine. Prim Health Care Res Dev. 2013; 14(2): 192–199.
  66. Nielsen S, Germanos R, Weier M, et al. The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews. Curr Neurol Neurosci Rep. 2018; 18(2): 8.
  67. Rosenberg EC, Tsien RW, Whalley BJ, et al. Cannabinoids and Epilepsy. Neurotherapeutics. 2015; 12(4): 747–768.
  68. Zhou D, Dennis E, Snehal I, et al. Cannabinoids in the Treatment of Epilepsy: A Review. European Medical Journal. 2021.
  69. Suraev AS, Todd L, Bowen MT, et al. An Australian nationwide survey on medicinal cannabis use for epilepsy: History of antiepileptic drug treatment predicts medicinal cannabis use. Epilepsy Behav. 2017; 70(Pt B): 334–340.
  70. Hussain SA, Zhou R, Jacobson C, et al. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome. Epilepsy Behav. 2015; 47: 138–141.
  71. Aguirre-Velázquez CG. Report from a Survey of Parents Regarding the Use of Cannabidiol in Mexican Children with Refractory Epilepsy. Neurol Res Int. 2017; 2017: 2985729.
  72. Tzadok M, Uliel-Siboni S, Linder I, et al. CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience. Seizure. 2016; 35: 41–44.
  73. Devinsky O, Patel AD, Cross JH, et al. GWPCARE3 Study Group. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. N Engl J Med. 2018; 378(20): 1888–1897.
  74. Thiele EA, Marsh ED, French JA, et al. GWPCARE4 Study Group. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018; 391(10125): 1085–1096.
  75. Devinsky O, Cross JH, Wright S, et al. Cannabidiol in Dravet Syndrome Study Group. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017; 376(21): 2011–2020.
  76. O'Connell BK, Gloss D, Devinsky O. Cannabinoids in treatment-resistant epilepsy: A review. Epilepsy Behav. 2017; 70(Pt B): 341–348.
  77. Ali S, Scheffer IE, Sadleir LG. Efficacy of cannabinoids in paediatric epilepsy. Dev Med Child Neurol. 2019; 61(1): 13–18.
  78. Billakota S, Devinsky O, Marsh E. Cannabinoid therapy in epilepsy. Curr Opin Neurol. 2019; 32(2): 220–226.
  79. Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav. 2013; 29(3): 574–577.
  80. Cladder-Micus MB, Speckens AEM, Vrijsen JN, et al. Mindfulness-based cognitive therapy for patients with chronic, treatment-resistant depression: A pragmatic randomized controlled trial. Depress Anxiety. 2018; 35(10): 914–924.
  81. Nakagawa A, Mitsuda D, Sado M, et al. Effectiveness of Supplementary Cognitive-Behavioral Therapy for Pharmacotherapy-Resistant Depression: A Randomized Controlled Trial. J Clin Psychiatry. 2017; 78(8): 1126–1135.
  82. Graczyk M, Łukowicz M, Dzierzanowski T. Prospects for the Use of Cannabinoids in Psychiatric Disorders. Front Psychiatry. 2021; 12: 620073.
  83. Bambico FR, Gobbi G. The cannabinoid CB1 receptor and the endocannabinoid anandamide: possible antidepressant targets. Expert Opin Ther Targets. 2008; 12(11): 1347–1366.
  84. Sales AJ, Crestani CC, Guimarães FS, et al. Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels. Prog Neuropsychopharmacol Biol Psychiatry. 2018; 86: 255–261.
  85. Silote GP, Sartim A, Sales A, et al. Emerging evidence for the antidepressant effect of cannabidiol and the underlying molecular mechanisms. J Chem Neuroanat. 2019; 98: 104–116.
  86. Soriano D, Brusco A, Caltana L. Further evidence of anxiety- and depression-like behavior for total genetic ablation of cannabinoid receptor type 1. Behav Brain Res. 2021; 400: 113007.
  87. Hill MN, Gorzalka BB. Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? Behav Pharmacol. 2005; 16(5-6): 333–352.
  88. Blaas K. Treating depression with cannabinoids. Cannabinoids. 2008; 3(2): 8–10.
  89. Witkin JM, Tzavara ET, Nomikos GG. A role for cannabinoid CB1 receptors in mood and anxiety disorders. Behav Pharmacol. 2005; 16(5-6): 315–331.
  90. Bambico FR, Katz N, Debonnel G, et al. Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J Neurosci. 2007; 27(43): 11700–11711.
  91. Huang WJ, Chen WW, Zhang X. Endocannabinoid system: Role in depression, reward and pain control (Review). Mol Med Rep. 2016; 14(4): 2899–2903.
  92. Swift W, Gates P, Dillon P. Survey of Australians using cannabis for medical purposes. Harm Reduct J. 2005; 2: 18.
  93. Brunt TM, van Genugten M, Höner-Snoeken K, et al. Therapeutic satisfaction and subjective effects of different strains of pharmaceutical-grade cannabis. J Clin Psychopharmacol. 2014; 34(3): 344–349.
  94. Woolridge E, Barton S, Samuel J, et al. Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage. 2005; 29(4): 358–367.
  95. Cuttler C, Spradlin A, McLaughlin RJ. A naturalistic examination of the perceived effects of cannabis on negative affect. J Affect Disord. 2018; 235: 198–205.
  96. Chadwick VL, Rohleder C, Koethe D, et al. Cannabinoids and the endocannabinoid system in anxiety, depression, and dysregulation of emotion in humans. Curr Opin Psychiatry. 2020; 33(1): 20–42.
  97. Selvarajah D, Gandhi R, Emery CJ, et al. Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care. 2010; 33(1): 128–130.
  98. Papagianni EP, Stevenson CW. Cannabinoid Regulation of Fear and Anxiety: an Update. Curr Psychiatry Rep. 2019; 21(6): 38.
  99. Janecki M, Graczyk M, Lewandowska AA, et al. Anti-Inflammatory and Antiviral Effects of Cannabinoids in Inhibiting and Preventing SARS-CoV-2 Infection. Int J Mol Sci. 2022; 23(8).
  100. Sarris J, Sinclair J, Karamacoska D, et al. Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review. BMC Psychiatry. 2020; 20(1): 24.
  101. Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 2011; 36(6): 1219–1226.
  102. Moltke J, Hindocha C. Reasons for cannabidiol use: a cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems. J Cannabis Res. 2021; 3(1): 5.
  103. Crippa JA, Derenusson GN, Ferrari TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol. 2011; 25(1): 121–130.
  104. Skelley JW, Deas CM, Curren Z, et al. Use of cannabidiol in anxiety and anxiety-related disorders. J Am Pharm Assoc (2003). 2020; 60(1): 253–261.
  105. O'Sullivan SE, Stevenson CW, Laviolette SR. Could Cannabidiol Be a Treatment for Coronavirus Disease-19-Related Anxiety Disorders? Cannabis Cannabinoid Res. 2021; 6(1): 7–18.
  106. Shannon S, Lewis N, Lee H, et al. Cannabidiol in Anxiety and Sleep: A Large Case Series. Perm J. 2019; 23: 18–041.
  107. White CM. A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential. J Clin Pharmacol. 2019; 59(7): 923–934.
  108. de Faria SM, de Morais Fabrício D, Tumas V, et al. Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson's disease. J Psychopharmacol. 2020; 34(2): 189–196.
  109. Wright M, Di Ciano P, Brands B. Use of Cannabidiol for the Treatment of Anxiety: A Short Synthesis of Pre-Clinical and Clinical Evidence. Cannabis Cannabinoid Res. 2020; 5(3): 191–196.
  110. Masataka N. Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders. Front Psychol. 2019; 10: 2466.
  111. Bahji A, Meyyappan AC, Hawken ER. Efficacy and acceptability of cannabinoids for anxiety disorders in adults: A systematic review & meta-analysis. J Psychiatr Res. 2020; 129: 257–264.
  112. Kaul M, Zee PC, Sahni AS. Effects of Cannabinoids on Sleep and their Therapeutic Potential for Sleep Disorders. Neurotherapeutics. 2021; 18(1): 217–227.
  113. Atkin T, Comai S, Gobbi G. Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery. Pharmacol Rev. 2018; 70(2): 197–245.
  114. Monti JM, Pandi-Perumal SR. Clinical Management of Sleep and Sleep Disorders With Cannabis and Cannabinoids: Implications to Practicing Psychiatrists. Clin Neuropharmacol. 2022; 45(2): 27–31.
  115. Chagas MHN, Eckeli AL, Zuardi AW, et al. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series. J Clin Pharm Ther. 2014; 39(5): 564–566.
  116. Suraev AS, Marshall NS, Vandrey R, et al. Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies. Sleep Med Rev. 2020; 53: 101339.
  117. Cameron C, Watson D, Robinson J. Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation. J Clin Psychopharmacol. 2014; 34(5): 559–564.
  118. Fraser GA. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther. 2009; 15(1): 84–88.
  119. Jetly R, Heber A, Fraser G, et al. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology. 2015; 51: 585–588.
  120. Roitman P, Mechoulam R, Cooper-Kazaz R, et al. Preliminary, open-label, pilot study of add-on oral Δ9-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clin Drug Investig. 2014; 34(8): 587–591.
  121. Orsolini L, Chiappini S, Volpe U, et al. Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD): A Systematic Review. Medicina (Kaunas). 2019; 55(9).
  122. Zhornitsky S, Potvin S. Cannabidiol in humans-the quest for therapeutic targets. Pharmaceuticals (Basel). 2012; 5(5): 529–552.
  123. Kesner AJ, Lovinger DM. Cannabinoids, Endocannabinoids and Sleep. Front Mol Neurosci. 2020; 13: 125.
  124. Birch E. The use of Indian hemp in the treatment of chronic chloral and chronic opium poisoning. The Lancet. 1889; 133(3422): 625.
  125. Scavone JL, Sterling RC, Van Bockstaele EJ. Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. Neuroscience. 2013; 248: 637–654.
  126. Hurd YL, Spriggs S, Alishayev J, et al. Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial. Am J Psychiatry. 2019; 176(11): 911–922.
  127. Ahmad T, Lauzon NM, de Jaeger X, et al. Cannabinoid transmission in the prelimbic cortex bidirectionally controls opiate reward and aversion signaling through dissociable kappa versus μ-opiate receptor dependent mechanisms. J Neurosci. 2013; 33(39): 15642–15651.
  128. Bergeria CL, Huhn AS, Dunn KE. The impact of naturalistic cannabis use on self-reported opioid withdrawal. J Subst Abuse Treat. 2020; 113: 108005.
  129. Bisaga A, Sullivan MA, Glass A, et al. The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. Drug Alcohol Depend. 2015; 154: 38–45.
  130. Ellis RJ, Wilson N, Peterson S. Cannabis and Inflammation in HIV: A Review of Human and Animal Studies. Viruses. 2021; 13(8).
  131. Zurier RB. Prospects for cannabinoids as anti-inflammatory agents. J Cell Biochem. 2003; 88(3): 462–466.
  132. van Niekerk G, Mabin T, Engelbrecht AM. Anti-inflammatory mechanisms of cannabinoids: an immunometabolic perspective. Inflammopharmacology. 2019; 27(1): 39–46.
  133. Nagarkatti P, Pandey R, Rieder SA, et al. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem. 2009; 1(7): 1333–1349.
  134. Mahmud MdS, Hossain MS, Ahmed AT, et al. Antimicrobial and Antiviral (SARS-CoV-2) Potential of Cannabinoids and : A Comprehensive Review. Molecules. 2021; 26(23).
  135. Ferber SG, Namdar D, Hen-Shoval D, et al. The "Entourage Effect": Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders. Curr Neuropharmacol. 2020; 18(2): 87–96.
  136. Henshaw FR, Dewsbury LS, Lim CK, et al. The Effects of Cannabinoids on Pro- and Anti-Inflammatory Cytokines: A Systematic Review of Studies. Cannabis Cannabinoid Res. 2021; 6(3): 177–195.
  137. Lowin T, Schneider M, Pongratz G. Joints for joints: cannabinoids in the treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2019; 31(3): 271–278.
  138. Sheriff T, Lin MJ, Dubin D, et al. The potential role of cannabinoids in dermatology. J Dermatolog Treat. 2020; 31(8): 839–845.
  139. Fabisiak A, Fichna J. Cannabinoids as gastrointestinal anti-inflammatory drugs. Neurogastroenterol Motil. 2017; 29(3).
  140. Rietcheck HR, Maghfour J, Rundle CW, et al. A Review of the Current Evidence Connecting Seborrheic Dermatitis and Parkinson's Disease and the Potential Role of Oral Cannabinoids. Dermatology. 2021; 237(6): 872–877.
  141. Petrosino S, Verde R, Vaia M, et al. Anti-inflammatory Properties of Cannabidiol, a Nonpsychotropic Cannabinoid, in Experimental Allergic Contact Dermatitis. J Pharmacol Exp Ther. 2018; 365(3): 652–663.
  142. Paland N, Pechkovsky A, Aswad M, et al. The Immunopathology of COVID-19 and the Cannabis Paradigm. Front Immunol. 2021; 12: 631233.
  143. Fine PG, Rosenfeld MJ. Cannabinoids for neuropathic pain. Curr Pain Headache Rep. 2014; 18(10): 451.
  144. Xiong W, Cui T, Cheng K, et al. Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors. J Exp Med. 2012; 209(6): 1121–1134.
  145. Anthony AT, Rahmat S, Sangle P, et al. Cannabinoid Receptors and Their Relationship With Chronic Pain: A Narrative Review. Cureus. 2020; 12(9): e10436.
  146. van Breemen RB, Muchiri RN, Bates TA, et al. Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants. J Nat Prod. 2022; 85(1): 176–184.
  147. Suryavanshi SV, Kovalchuk I, Kovalchuk O. Cannabinoids as Key Regulators of Inflammasome Signaling: A Current Perspective. Front Immunol. 2020; 11: 613613.
  148. Russo EB. Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. Cannabis Cannabinoid Res. 2016; 1(1): 154–165.
  149. Hill MN, Patel S. Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses. Biol Mood Anxiety Disord. 2013; 3(1): 19.
  150. Morena M, Patel S, Bains JS, et al. Neurobiological Interactions Between Stress and the Endocannabinoid System. Neuropsychopharmacology. 2016; 41(1): 80–102.
  151. Hillard CJ. Stress regulates endocannabinoid-CB1 receptor signaling. Semin Immunol. 2014; 26(5): 380–388.
  152. De Laurentiis A, Fernandez-Solari J, Mohn C, et al. The hypothalamic endocannabinoid system participates in the secretion of oxytocin and tumor necrosis factor-alpha induced by lipopolysaccharide. J Neuroimmunol. 2010; 221(1-2): 32–41.
  153. Micale V, Drago F. Endocannabinoid system, stress and HPA axis. European Journal of Pharmacology. 2018; 834: 230–239.
  154. deRoon-Cassini TA, Stollenwerk TM, Beatka M, et al. Meet Your Stress Management Professionals: The Endocannabinoids. Trends Mol Med. 2020; 26(10): 953–968.
  155. Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007; 370(9600): 1706–1713.
  156. Mitchell PB, Morris MJ. Depression and anxiety with rimonabant. Lancet. 2007; 370(9600): 1671–1672.
  157. Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses. 2006; 66(2): 234–246.



Palliative Medicine in Practice